From the Journals

MIS-C cardiac evaluation requires more than EF



Comprehensive LV evaluation needed

The findings reinforce that myocardial involvement is more frequent and sometimes more severe in MIS-C than previously thought, said Kevin G. Friedman, MD, a pediatrician at Harvard Medical School, Boston, and an attending physician in the department of cardiology at Boston Children’s Hospital. “We are underestimating it by using just traditional measures like ejection fraction. It requires a comprehensive evaluation of left ventricular function; it really affects all aspects of the ventricle, both the systolic function and the diastolic function.”

Dr. Kevin G. Friedman, a pediatrician at Harvard Medical School, Boston, and an attending physician in the department of cardiology at Boston Children's Hospital

Dr. Kevin G. Friedman

This study supports that MIS-C patients should have a more detailed analysis than EF on echocardiography, including strain imaging. “Probably these patients should all be followed at centers where they can evaluate a more detailed analysis of the LV and RV function,” he said. Patients with ongoing CA enlargement and LV dysfunction should have follow-up cardiac care indefinitely. Patients who have no cardiac symptoms during the acute phase probably don’t need long-term follow-up.

“We’re just trying to learn more about this disease, and it’s certainly concerning that so many kids are having cardiac involvement,” Dr. Friedman said. “Fortunately they’re getting better; we’re just trying to find out what this means for the long term.”

Dr. Matsubara and Dr. Friedman have no relevant financial disclosures.

SOURCE: Matsubara D et al. J Am Coll Cardiol. 2020 Sep 2. doi: 10.1016/j.jacc.2020.08.056.


Recommended Reading

Prior beta-blockers predict extra burden of heart failure in women with ACS
The Hospitalist
Heart damage even after COVID-19 ‘recovery’ evokes specter of later heart failure
The Hospitalist
Early palliative care fails to improve QOL in advanced heart failure
The Hospitalist
ACC panel defines, advises on heart failure with ‘recovered’ EF
The Hospitalist
PVR reassessed as predictor of heart failure
The Hospitalist
Non-COVID-19 clinical trials grind to a halt during pandemic
The Hospitalist
First evidence of SARS-CoV-2 in heart cells
The Hospitalist
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects
The Hospitalist
COVID-19 at home: What does optimal care look like?
The Hospitalist
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
The Hospitalist
   Comments ()